Some promising preliminary results have been obtained with the use of licartin, a novel drug in which metuximab (a monoclonal antibody targeting HAb18G/CD147, an antigen overexpressed in HCC) is conjugated to the radioisotope [131]. The gene discussed is BSG; the disease is hepatocellular carcinoma.